Welcome to LookChem.com Sign In|Join Free

CAS

  • or

882678-96-8

Post Buying Request

882678-96-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 99.0%high purity 3-Amino-2-methylphenylboronic acid, pinacol ester, CAS 882678-96-8 CAS NO.882678-96-8

    Cas No: 882678-96-8

  • USD $ 7.0-8.0 / Metric Ton

  • 1 Metric Ton

  • 1000 Metric Ton/Day

  • KAISA GROUP INC
  • Contact Supplier

882678-96-8 Usage

General Description

3-Amino-2-methylphenylboronic acid, pinacol ester is a chemical compound that belongs to the class of boronic acids. It is an ester derivative of 3-amino-2-methylphenylboronic acid, with the pinacol moiety serving as the ester group. 3-Amino-2-methylphenylboronic acid, pinacol ester is commonly used in organic synthesis as a reagent for the construction of carbon-carbon and carbon-heteroatom bonds. It is also utilized in the development of pharmaceuticals and agrochemicals. Additionally, its reactivity and versatility make it a valuable building block for the preparation of various complex molecules in the fields of medicinal chemistry and materials science.

Check Digit Verification of cas no

The CAS Registry Mumber 882678-96-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,2,6,7 and 8 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 882678-96:
(8*8)+(7*8)+(6*2)+(5*6)+(4*7)+(3*8)+(2*9)+(1*6)=238
238 % 10 = 8
So 882678-96-8 is a valid CAS Registry Number.
InChI:InChI=1/C13H20BNO2/c1-9-10(7-6-8-11(9)15)14-16-12(2,3)13(4,5)17-14/h6-8H,15H2,1-5H3

882678-96-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline

1.2 Other means of identification

Product number -
Other names 3-AMINO-2-METHYLPHENYLBORONIC ACID,PINACOL ESTER

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:882678-96-8 SDS

882678-96-8Relevant articles and documents

1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton's tyrosine kinase

Kraj?ovi?ová, Soňa,Jorda, Radek,Vanda, David,Soural, Miroslav,Kry?tof, Vladimír

, (2020/12/21)

Herein, we report an efficient synthetic approach towards trisubstituted imidazo [4,5-c]pyridines designed as inhibitors of Bruton's tyrosine kinase (BTK). Two alternative synthetic routes for the simple preparation of desired compounds with variable substitutions at the N1, C4, C6 positions were introduced with readily available building blocks. Further, the developed synthetic approach was feasible for isomeric compounds bearing imidazo [4,5-b]pyridine scaffolds. In contrast to expectations based on previous studies, the imidazo [4,5-c]pyridine inhibitor exhibited a significantly higher activity against BTK compared to its imidazo [4,5-b]pyridine isomer. An inherent SAR study in the series of imidazo [4,5-c]pyridine compounds revealed a remarkably high tolerance of C6 substitutions for both hydrophobic and hydrophilic substituents. Preliminary cellular experiments indicated selective BTK targeting in Burkitt lymphoma and mantle cell lymphoma cell lines. The inhibitors could thus serve as starting points for further development, eventually leading to BTK inhibitors that could be used after ibrutinib failure.

Compound capable of being used as immunomodulator, and preparation method and application thereof

-

Paragraph 0094-0098, (2021/10/13)

The invention relates to a micromolecular immunomodulator and discloses a method for preparing the micromolecular immunomodulator at the same time, and the micromolecular immunomodulator can be used for treating cancers or tumors, infectious diseases, metabolic diseases and other diseases and has great clinical value.

Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)

Watterson, Scott H.,Liu, Qingjie,Beaudoin Bertrand, Myra,Batt, Douglas G.,Li, Ling,Pattoli, Mark A.,Skala, Stacey,Cheng, Lihong,Obermeier, Mary T.,Moore, Robin,Yang, Zheng,Vickery, Rodney,Elzinga, Paul A.,Discenza, Lorell,D'Arienzo, Celia,Gillooly, Kathleen M.,Taylor, Tracy L.,Pulicicchio, Claudine,Zhang, Yifan,Heimrich, Elizabeth,McIntyre, Kim W.,Ruan, Qian,Westhouse, Richard A.,Catlett, Ian M.,Zheng, Naiyu,Chaudhry, Charu,Dai, Jun,Galella, Michael A.,Tebben, Andrew J.,Pokross, Matt,Li, Jianqing,Zhao, Rulin,Smith, Daniel,Rampulla, Richard,Allentoff, Alban,Wallace, Michael A.,Mathur, Arvind,Salter-Cid, Luisa,Macor, John E.,Carter, Percy H.,Fura, Aberra,Burke, James R.,Tino, Joseph A.

, (2019/04/17)

Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling. BTK also plays a critical role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fc receptor in granulocytes, and the RANK receptor in osteoclasts. As a result, pharmacological inhibition of BTK is anticipated to provide an effective strategy for the clinical treatment of autoimmune diseases such as rheumatoid arthritis and lupus. This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose. With excellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has advanced into clinical studies.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 882678-96-8